72,822 codes were added to the 2016 ICD-10-PCS code set, effective October 1, 2015.
Displaying codes 72,801-72,822 of 72,822:
HZ95ZZZ Pharmacotherapy for Substance Abuse Treatment, Naloxone
HZ96ZZZ Pharmacotherapy for Substance Abuse Treatment, Clonidine
HZ97ZZZ Pharmacotherapy for Substance Abuse Treatment, Bupropion
HZ98ZZZ Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication
HZ99ZZZ Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication
X2C New Technology, Cardiovascular System, Extirpation
X2C0361 Extirpation of Matter from Coronary Artery, One Site using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
X2C1361 Extirpation of Matter from Coronary Artery, Two Sites using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
X2C2361 Extirpation of Matter from Coronary Artery, Three Sites using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
X2C3361 Extirpation of Matter from Coronary Artery, Four or More Sites using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
XR2 New Technology, Joints, Monitoring
XR2G021 Monitoring of Right Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
XR2H021 Monitoring of Left Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
XW0 New Technology, Anatomical Regions, Introduction
XW03321 Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW03331 Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW03341 Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW03351 Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1
XW04321 Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
XW04331 Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1
XW04341 Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
XW04351 Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1
